InnoCare Pharma Limited (SHA:688428)
China
· Delayed Price · Currency is CNY 20.60
+0.15 (0.73%)
At close: May 9, 2025, 2:57 PM CST
InnoCare Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Net Income | -440.63 | -631.26 | -886.59 | -64.55 | -391.4 | Upgrade
|
| Depreciation & Amortization | 95.59 | 88.15 | 68.8 | 33.08 | 11.19 | Upgrade
|
| Other Amortization | 11.54 | 11.23 | 9.85 | 0.63 | 0.27 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | 0 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.12 | 0.02 | -6.77 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -6.26 | -5.57 | 1.44 | -6.7 | - | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | 0.6 | - | Upgrade
|
| Stock-Based Compensation | -10.79 | 65.1 | 129.48 | 126.44 | 215.62 | Upgrade
|
| Provision & Write-off of Bad Debts | 1.5 | 0.27 | 0.1 | - | - | Upgrade
|
| Other Operating Activities | 1.88 | 49.17 | 200.51 | -40.75 | 48.35 | Upgrade
|
| Change in Accounts Receivable | -63.34 | -194.53 | -24.56 | -45.15 | -0.12 | Upgrade
|
| Change in Inventory | 47.65 | -42.46 | -52.12 | -8.04 | -1.88 | Upgrade
|
| Change in Accounts Payable | -2.8 | -5.61 | 69.28 | 79.08 | -2.68 | Upgrade
|
| Change in Unearned Revenue | - | - | - | 17.19 | -51.39 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | 75.22 | -0.49 | Upgrade
|
| Operating Cash Flow | -365.55 | -665.49 | -490.58 | 167.06 | -172.52 | Upgrade
|
| Capital Expenditures | -78.23 | -254.65 | -370.33 | -169.77 | -251 | Upgrade
|
| Sale of Property, Plant & Equipment | 0 | 0.01 | - | 0.02 | - | Upgrade
|
| Cash Acquisitions | - | 1.15 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | -1.44 | -0.27 | Upgrade
|
| Investment in Securities | 1,056 | 795.85 | -1,529 | -1,638 | -889.03 | Upgrade
|
| Other Investing Activities | 133.75 | 118.71 | 98.37 | 79.57 | 33.34 | Upgrade
|
| Investing Cash Flow | 1,111 | 661.06 | -1,801 | -1,730 | -1,107 | Upgrade
|
| Long-Term Debt Issued | 1,185 | 33.8 | 325 | 50 | - | Upgrade
|
| Total Debt Issued | 1,185 | 33.8 | 325 | 50 | - | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -9.02 | Upgrade
|
| Long-Term Debt Repaid | -990.41 | -28.98 | -21.77 | -14.92 | -4.99 | Upgrade
|
| Total Debt Repaid | -990.41 | -28.98 | -21.77 | -14.92 | -14.02 | Upgrade
|
| Net Debt Issued (Repaid) | 194.91 | 4.82 | 303.23 | 35.08 | -14.02 | Upgrade
|
| Issuance of Common Stock | 18.5 | 9.95 | 2,923 | 2,527 | 2,356 | Upgrade
|
| Repurchase of Common Stock | -13.35 | -6.3 | - | - | - | Upgrade
|
| Common Dividends Paid | -362.93 | -1.15 | -3.26 | - | - | Upgrade
|
| Other Financing Activities | -122.73 | -6.01 | -128.69 | -17.74 | -103.87 | Upgrade
|
| Financing Cash Flow | -285.59 | 1.31 | 3,095 | 2,545 | 2,238 | Upgrade
|
| Foreign Exchange Rate Adjustments | 16.92 | 25.7 | 139.9 | -45.3 | -251.78 | Upgrade
|
| Net Cash Flow | 476.9 | 22.58 | 942.5 | 936.6 | 706.73 | Upgrade
|
| Free Cash Flow | -443.78 | -920.14 | -860.91 | -2.71 | -423.51 | Upgrade
|
| Free Cash Flow Margin | -43.96% | -124.59% | -137.66% | -0.26% | -31049.41% | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -0.54 | -0.58 | -0.00 | -0.44 | Upgrade
|
| Cash Interest Paid | - | - | - | 2.53 | 1.14 | Upgrade
|
| Cash Income Tax Paid | 89.25 | 58.78 | 18.89 | - | - | Upgrade
|
| Levered Free Cash Flow | -664.21 | -814.43 | -160.44 | 35.82 | -412.99 | Upgrade
|
| Unlevered Free Cash Flow | -643.09 | -792.42 | -149.57 | 37.47 | -412.28 | Upgrade
|
| Change in Net Working Capital | 320.74 | 282.45 | -469.26 | -162.6 | 38.72 | Upgrade
|
Updated Nov 11, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.